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ecules (13); however, their capacity to efficiently present antigens 



























































































siRNA-PEI nanoparticles are preferentially engulfed by tumor-asso-
ciated DCs. (A) NTsiRNA-PEI were stained with uranyl acetate and 
visualized using transmission electron microscopy. Original magnifica-
tion, ×145,000 (left); ×285,000 (right). Scale bars: 20 nm (left); 100 nm 
(right). Average nanoparticle size was 40–60 nm. (B) Selective engulf-
ment of NTsiRNA-PEI by peritoneal tumor-associated CD11c+ DCs. 
Rhodamine-labeled NTsiRNA-PEI were intraperitoneally injected into 
mice bearing ID8-Defb29/Vegf-A ovarian carcinoma, and peritoneal 
wash samples were analyzed by FACS after 3 days. (C) Time-course 
analysis of nanocomplex uptake by peritoneal CD11c+ DCs in tumor-
bearing mice after a single intraperitoneal injection. The percentage 
of cells retaining the nanoparticles is indicated for each time point. 
Data are representative of 3 mice analyzed per time point in 2 inde-
pendent experiments. (D) Biodistribution of intraperitoneally injected 
siRNA-PEI nanoparticles. Ovarian carcinoma–bearing mice received 
a single intraperitoneal injection of rhodamine-labeled NTsiRNA-PEI, 
and multiple organs were collected at different time points after injec-
tion. Fluorescence microscopy was performed on histological sections 
from different organs to determine the presence of nanoparticles. Red 
indicates rhodamine-labeled nanocomplexes. Blue denotes nuclei. 
Data are representative of at least 3 independent experiments. Origi-
nal magnification, ×200; ×40 (inset). (E) Nanoparticle uptake by DCs 
infiltrating solid ovarian tumors. Ovaries from tumor-bearing mice were 
collected at different time points after a single intraperitoneal injec-
tion with rhodamine-labeled NTsiRNA-PEI. Shown is the percentage 
of ovarian tumor–resident DCs engulfing nanoparticles in situ, deter-
mined by FACS. Data are representative of 2 independent experi-
ments. SSC-A, side-scattered light.
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contrast,  virtually all CD11c+ DCs engulfing NTsiRNA-PEI 
at tumor locations showed increased surface levels of CD80, 













Engulfment of PEI-based nanocomplexes induces maturation of tumor-associated DCs in vivo and in situ. (A) Expression of CD80 and MHC-II on 
tumor-associated DCs from mice bearing ID8-Defb29/Vegf-A tumors for 3 weeks and injected with PBS. (B) Rhodamine-labeled NTsiRNA-PEI 
or (C) equivalent amounts of rhodamine-labeled PEI alone (see Methods) were intraperitoneally injected into mice bearing ID8-Defb29/Vegf-A 
tumors for 3 weeks. Expression of CD80, MHC-I, and MHC-II on tumor DCs that engulfed the nanoparticles or PEI was analyzed by FACS 3 days 
later. Rhod, rhodamine-labeled PEI. Filled histograms represent expression on DCs that did not engulf nanoparticles or PEI. Open histograms 
indicate expression by DCs that engulfed nanoparticles or PEI in the same host. Data are representative of 3 mice per group in 4 independent 
experiments. In A–C, the percentage of tumor-associated DCs coexpressing MHC-II and CD80 is indicated. (D) siRNA-PEI nanoparticles 
induced maturation of human tumor DCs. Leukocytes from 6 unselected dissociated stage III human ovarian tumors were enriched by Ficoll, 
5 × 106 cells were incubated in 5 ml RPMI containing 100 μl PBS (dotted histograms) or 100 μl NTsiRNA-PEI (open histograms; see Methods), 
and the levels of CD80 on CD45+DEC205+CD3–CD20–CD14– tumor DCs were analyzed by FACS 18 hours later. Filled histograms represent 
staining with isotype control antibodies. MFI, mean fluorescence intensity of CD80 staining. Data points and horizontal bars denote individual 
values and means, respectively. **P < 0.01 (Mann-Whitney).
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siRNA-PEI nanocomplexes enhance antigen 























































siRNA-PEI nanoparticles enhance antigen presentation and induce tumoricidal activity by ovarian 
cancer DCs. (A) Improved antigen-processing capacity of tumor DCs engulfing PEI-based nano-
complexes in vivo. Mice bearing ID8-Defb29/Vegf-A tumors were intraperitoneally injected with 
DQ-OVA (see Methods), and 24 hours later received a single intraperitoneal injection of PBS, PEI, 
or NTsiRNA-PEI (3 mice per group, 2 independent experiments). Percentages denote the propor-
tion of peritoneal tumor-associated DCs that efficiently processed the probe (FITC+), determined 
by FACS 48 hours later. (B) Enhanced antigen-presenting ability of OVA-pulsed tumor DCs (tDCs) 
engulfing siRNA-PEI nanoparticles in vivo (see Methods). Shown are representative FACS analy-
sis of CFSE dilution and graphical representation of percent proliferating cells in triplicate for each 
condition. (C) Uptake of siRNA-PEI nanocomplexes induced tumoricidal DCs. Tumor-bearing mice 
were intraperitoneally injected with PBS, PEI, or NTsiRNA-PEI; 36 hours later, CD11c+MHC-II+CD3–
NK1.1– tumor DCs from each group were sorted and incubated with 51Cr-labeled ID8-Defb29/Vegf-A 
cells. Release of 51Cr was measured in cell supernatants 5 hours later. Radiolabeled tumor cells 
were also cocultured with C57BL/6 splenocytes preincubated with 1,000 U/ml IL-2 for 5 days as a 
positive control of lysis. (D) Quantification of TRAIL mRNA levels by real-time RT-PCR in the same 
tumor DCs as in C. Error bars in B–D denote SEM. **P < 0.01.
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siRNA-PEI nanoparticles stimulate multiple TLRs in vitro and in vivo. (A) siRNA-PEI nanocomplexes dose-dependently stimulated TLR3, TLR5, 
and TLR7 in vitro. Cotransfected HEK293 cells were stimulated with increasing amounts of siRNA-PEI nanoparticles or positive control ago-
nists (+) as described in Methods. Data are representative of 4 independent experiments. (B) PEI was sufficient to stimulate TLR5 in vitro in 
a dose-dependent manner. HEK293 cells expressing TLR5 and harboring an NF-κB–dependent luciferase reporter plasmid were stimulated 
with increasing amounts of PEI, proteinase K (Prot K), or PEI treated overnight at 55°C with proteinase K (1 mg/ml), and luciferase activity was 
measured as described in Methods. Data are representative of 3 independent experiments. (C) PEI induced rapid cytokine secretion in vivo in a 
TLR5-dependent manner. Naive WT or Tlr5–/– mice were intraperitoneally injected with 5% glucose (gluc) or linear PEI, and serum levels of KC 
and IP-10 were determined 2 hours later by cytokine assay (see Methods). Data are representative of 4 mice per group, 2 independent experi-
ments. (D) PEI-complexed siRNA induced MyD88-dependent secretion of IFN-β at tumor locations. Ascites from Myd88+/– or Myd88–/– mice 
bearing advanced ID8-Defb29/Vegf-A ovarian tumors were collected prior to (Basal) and 3 hours after intraperitoneal administration of PEI 
or NTsiRNA-PEI, and levels of IFN-β were analyzed by ELISA. Data are representative of 4 mice per group, 2 independent experiments. (E) 
CD45+CD11c+MHC-II+ tumor DCs were sorted from the peritoneal cavity of mice bearing ID8-Defb29/Vegf-A tumors, and TLR expression was 
confirmed by RT-PCR. Error bars in A–D denote SEM. *P < 0.05; **P < 0.01.
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siRNA-PEI nanocomplexes prolong survival in a T cell–mediated, MyD88-dependent manner. (A and B) Mice bearing aggressive ID8-Defb29/
Vegf-A (A) or luciferase-expressing parental ID8 (B) tumors were treated intraperitoneally with PBS or NTsiRNA-PEI nanoparticles at days 8, 
13, 18, 23, and 27 after tumor challenge, and survival was monitored over time. Data are representative of 2 independent experiments with a 
total of 12 mice per group. (C) Mice bearing preestablished luciferase-expressing parental ID8 ovarian tumors were intraperitoneally treated 
with PBS or NTsiRNA-PEI as described above, and luciferin was injected 70 days after tumor challenge to monitor tumor burden in vivo. (D) 
Quantification of the tumor burden shown in C. (E) Nanoparticle-mediated increase in survival was completely MyD88 dependent. Myd88+/– or 
Myd88–/– mice bearing aggressive ID8-Defb29/Vegf-A ovarian tumors were treated with PBS or NTsiRNA-PEI as described above, and survival 
was monitored over time. Data are representative of 2 independent experiments with a total of 10 mice per group. (F) Treatment with siRNA-PEI 
nanocomplexes induced T cell–mediated antitumor protective immunity. CD3+ T cells (3 × 106) purified from the spleens of mice treated with PBS 
or NTsiRNA-PEI were intravenously transferred into naive C57BL/6 mice previously irradiated with 3 Gy (n = 5 per group); after 24 hours, mice 
were challenged in the flank with ID8-Defb29/Vegf-A ovarian carcinoma cells. Tumor pictures were taken 2 months later. (G) Quantification of 
tumor size from F. In D and G, data points and horizontal bars denote individual values and means, respectively. *P < 0.05; **P < 0.01 versus 
respective PBS control, log-rank test (A, B, and E) or Mann-Whitney test (D and G).
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siRNA-PEI nanoparticle treatment prolongs survival in a MyD88-













PD-L1 on ovarian cancer–associated DCs inhibits antigen-specific T cell responses. (A) FACS analysis of PD-L1 expression on HEK293 cells 
(negative control) or CD45+DEC205+VE-cadherin+ DCs infiltrating 5 unselected dissociated stage III human tumors. Dotted histograms represent 
isotype control staining. (B) Representative immunohistochemistry of PD-L1+ cells surrounding a tumor islet in a human ovarian carcinoma speci-
men. Original magnification, ×200. (C) PD-1 expression on control HEK293 cells and tumor-infiltrating lymphocytes (TILs) matching the human 
specimens in A. Dotted histogram represents isotype control staining; filled histogram demonstrates negative PD-1 staining. The percentage 
of human tumor-infiltrating T cells that express PD-1 is indicated. (D) PD-L1 expression by peritoneal tumor DCs in mice bearing advanced 
ID8-Defb29/Vegf-A ovarian carcinoma. The percentage of CD11c+ cells coexpressing PD-L1 is indicated. (E) Representative FACS analysis 
of PD-1 expression by T cells infiltrating mouse ID8-Defb29/Vegf-A ovarian tumors. Filled histograms indicate isotype control; open histograms 
show PD-1 staining. The percentage of mouse tumor-infiltrating T cells expressing PD-1 is indicated. (F) Representative FACS analyses of mice 
transferred with PD-L1–blocked DCs compared with both a mouse that did not receive DCs (left) and a mouse transferred with DCs incubated 
with corresponding isotype control antibodies (iAb; right).
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Treatment with PD-L1–siRNA-PEI induces enhanced therapeutic effects. (A) Ascites cells from mice bearing ID8-Defb29/Vegf-A tumors were 
left untreated or transfected in vitro with PD-L1–siRNA-PEI or NTsiRNA-PEI, and PD-L1 mRNA levels were measured 48 hours later by real-
time RT-PCR. Experiments were repeated 3 times with similar results. (B) Silencing PD-L1 on tumor DCs in vivo. Tumor-bearing mice were 
intraperitoneally injected with rhodamine-labeled PD-L1–siRNA-PEI or NTsiRNA-PEI, and PD-L1 expression in tumor DCs that engulfed the 
nanocomplexes was determined by FACS. Experiments were repeated twice with similar results. (C) Mice bearing aggressive ID8-Defb29/Vegf-A 
tumors were treated intraperitoneally as described in Methods, and survival was monitored over time. Data are representative of 2 independent 
experiments, 12 mice per group. Significant differences were as follows: anti–PD-L1 versus isotype control antibodies (P < 0.05), NTsiRNA-PEI 
versus PBS (P < 0.01), PD-L1–siRNA-PEI versus anti–PD-L1 (P < 0.05), and PD-L1–siRNA-PEI versus NTsiRNA-PEI (P < 0.05). (D–G) Improved 
antitumor immune responses at tumor locations in mice treated with PD-L1–siRNA-PEI. Tumor-bearing mice (n = 3 per group, 3 independent 
experiments) were treated as described above, and peritoneal wash samples were analyzed at day 27. (D) CD4+ and CD8+ T cell infiltration in the 
peritoneal cavities of treated mice. (E) Representative ELISPOT analysis showing increased numbers of IFN-γ–producing cells in mice treated 
with PD-L1–siRNA-PEI. (F) Proportion of activated tumor-specific CD8+ T cells infiltrating the peritoneal cavities of mice. Data points and horizontal 
bars denote individual values and means, respectively. (G) Representative FACS analysis of F. The percentage of tumor-reactive CD8+ T cells 
coexpressing the activation markers CD44 and CD69 is indicated. Error bars in A, B, D, and E denote SEM. *P < 0.05; **P < 0.01.
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Tumor-associated DCs suppress antigen-specific immune responses 

















To  confirm  the  functional  relevance  of  PD-L1  specifically 
expressed on tumor DCs in vivo, we sorted PD-L1+CD45+CD11c+ 
VE-cadherin+ DCs from the ascites of mice growing intraperitoneal 
ID8-Defb29/Vegf-A  tumors  (9).  In  this aggressive ovarian can-
cer model,  tumor-infiltrating DCs (9), but not tumor cells or 







Increased proportion of antitumor central memory–like T cells in the bone marrow of mice treated with PD-L1–siRNA-PEI. (A) Percentage of 
tumor-reactive CD8+ T cells expressing central memory markers in the bone marrow of mice treated with PD-L1–siRNA-PEI. (B) Representative 
FACS analysis of A. (C) Proportion of global CD8+ T cells exhibiting a central memory–like phenotype in the bone marrow of tumor-bearing mice. 
Data are representative of 3 independent experiments with similar results. (D) Representative FACS analysis of C. *P < 0.05. In B and D, the 
percentage of tumor-reactive or global CD8+ T cells coexpressing the central memory markers CD44 and CD62L is indicated.
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While  the  intrinsic  immunostimulatory  capacity of  siRNA 
has raised concerns about the consequences of using these mol-
ecules in a clinical setting (18), we demonstrated that the inher-
ent capacity of  siRNA-PEI nanocomplexes  to activate  innate 
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